Clinical Trials Browser

Phase 2 × lutetium Lu 177 dotatate × Endocrine × Clear all

NCT05724108 2026-03-18

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Phase 2 Active not recruiting

Neuroendocrine Tumors

NCT05773274 2026-03-18

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Phase 2 Recruiting

Metastatic Digestive System Neuroendocrine Tumor G1

NCT04665739 2026-03-17

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Phase 2 Recruiting

Advanced Lung Neuroendocrine Tumor

NCT03206060 2026-02-17

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Phase 2 Recruiting

CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04711135 2026-02-12

NETTER-P

Phase 2 Active not recruiting

11 enrolled 14 charts 1 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT04954820 2026-02-05

ReLUTH

Phase 2 Recruiting

Neuroendocrine Tumors, Disease Progression

NCT05987176 2026-01-14

NELMAS

Phase 2 Terminated

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT03457948 2025-09-03

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Phase 2 Active not recruiting

Neuroendocrine Tumors

NCT06395402 2025-07-22

LUMOD-ID

Phase 2 Recruiting

Neuroendocrine Tumors

NCT07012330 2025-06-10

Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

Phase 2 Terminated

Neoplasms, Neuroendocrine Tumors

NCT02489604 2025-01-13

LUNET

Phase 2 Terminated

Neuroendocrine Tumors

NCT06607692 2024-10-21

LUPARPED

Phase 2 Recruiting

CNSEndocrineNET

Adrenal Gland Neoplasms, Medulloblastoma, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT02236910 2024-10-15

Lu-DOTA-TATE

Phase 2 Unknown

Carcinoma, Neuroendocrine

NCT02754297 2024-08-21

P-PRRT

Phase 2 Active not recruiting

Carcinoid Tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04385992 2023-06-27

NeoLuPaNET

Phase 2 Completed

Neuroendocrine Tumors

NCT05894486 2023-06-08

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Phase 2 Not yet recruiting

Neuroendocrine Tumors

NCT01237457 2023-03-20

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Phase 2 Completed

Neuroendocrine Tumors

NCT04525638 2022-08-02

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Phase 2 Unknown

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Phase 2 Withdrawn

CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

NCT04039516 2020-08-04

CHARRT

Phase 2 Unknown

Carcinoid Heart Disease, Carcinoid Tumor, Serotonin Syndrome

NCT04029428 2020-04-01

POLNETS_PRRT

Phase 2 Unknown

CNSEndocrineNET

Paraganglioma, Neuroendocrine Tumors